FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

FBLG 10.11.2024

Full Press ReleaseSEC FilingsOur FBLG Tweets

About Gravity Analytica

Recent News

  • 12.30.2024 - FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
  • 12.23.2024 - FibroBiologics Announces $25 Million Financing
  • 11.19.2024 - FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Recent Filings

  • 01.17.2025 - POS AM Post-Effective amendments for registration statement
  • 01.14.2025 - 424B4 Prospectus [Rule 424(b)(4)]
  • 01.14.2025 - EFFECT Notice of Effectiveness

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

October 11, 2024 9:31am EDTDownload as PDF

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O’Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

For more information, please visit FibroBiologics'websiteor email FibroBiologics at:info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visitwww.FibroBiologics.com.

General Inquiries:info@fibrobiologics.com

Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@russopr.com

Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com

Primary Logo

Source: Fibrobiologics, Inc.

Released October 11, 2024

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com